Possible new antiaging strategies related to neuroendocrine-immune interactions

NeuroImmunoModulation

Volumn 15, Issue 4-6, 2008, Pages 344-350

  Mocchegiani, Eugenio ^a   Malavolta, Marco ^a  

^a INRCA   (Italy)

Author keywords

Antiaging strategies; Carnosine; Ghrelin; L deprenyl; Leptin; Neuroendocrine immune interactions; NO donors; Zinc

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTIDEPRESSANT AGENT; CARNOSINE; CYTOKINE; GAMMA INTERFERON; GHRELIN; GROWTH HORMONE; INTERLEUKIN 2; INTERLEUKIN 6; LEPTIN; NEUROTRANSMITTER; NITRIC OXIDE; SCAVENGER; SELEGILINE; TUMOR NECROSIS FACTOR ALPHA; ZINC ION;

AGING; ANTIOXIDANT ACTIVITY; BIOAVAILABILITY; BIOLOGICAL ACTIVITY; CELL AGING; CELL RENEWAL; CYTOKINE PRODUCTION; CYTOTOXICITY; HORMONE SYNTHESIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; LEARNING; LIFESPAN; LONG TERM MEMORY; NATURAL KILLER CELL; NEUROENDOCRINE SYSTEM; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SENILE CATARACT; VISUAL IMPAIRMENT;

ADULT; AGED; AGING; ANIMALS; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; CARNOSINE; CHILD, PRESCHOOL; DOGS; FEMALE; GHRELIN; HUMANS; LEPTIN; LONGEVITY; MALE; NEUROIMMUNOMODULATION; NITRIC OXIDE DONORS; SELEGILINE; YOUNG ADULT; ZINC;

EID: 57149099401     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000156476     Document Type: Review

References (72)

1. Paolisso G, Barbieri M, Bonafe M, Franceschi C: Metabolic age modelling: the lesson from centenarians. Eur J Clin Invest 2000;30:888-894.
2. Mocchegiani E, Santarelli L, Costarelli L, Cipriano C, Muti E, Giacconi R, Malavolta M: Plasticity of neuroendocrine-thymus interactions during ontogeny and ageing: role of zinc and arginine. Ageing Res Rev 2006;5:281-309.
3. Webster JI, Tonelli L, Sternberg EM: Neuroendocrine regulation of immunity. Annu Rev Immunol 2002;20:125-163.
4. Cardinali DP, Brusco LI, Cutrera RA, Castrillón P, Esquifino AI: Melatonin as a time-meaningful signal in circadian organization of immune response. Biol Signals Recept 1999;8:41-48.
5. Savino W, Arzt E, Dardenne M: Immunoneuroendocrine connectivity: the paradigm of the thymus-hypothalamus/pituitary axis. Neuroimmunomodulation 1999;6:126-136.
6. Chimienti F, Favier A, Seve M: ZnT-8, a pancreatic β-cell-specific zinc transporter. Biometals 2005;18:313-317.
7. Licastro F, Moccheiani E, Masi M, Fabris N: Modulation of the neuroendocrine system and immune functions by zinc supplementation in children with Down's syndrome. J Trace Elem Electrolytes Health Dis 1993;7:237-239.
8. Mocchegiani E, Giacconi R, Cipriano C, Gasparini N, Orlando F, Stecconi R, Muzzioli M, Isani G, Carpenè E: Metallothioneins (I+II) and thyroid-thymus axis efficiency in old mice: role of corticosterone and zinc supply. Mech Ageing Dev 2002;123:675-694.
9. Mocchegiani E, Bulian D, Santarelli L, Tibaldi A, Muzzioli M, Pierpaoli W, Fabris N: The immuno-reconstituting effect of melatonin or pineal grafting and its relation to zinc pool in aging mice. J Neuroimmunol 1994;53:189-201.
10. Zwirska-Korczala K, Adamczyk-Sowa M, Sowa P, Pilc K, Suchanek R, Pierzchala K, Namyslowski G, Misiolek M, Sodowski K, Kato I, Kuwahara A, Zabielski R: Role of leptin, ghrelin, angiotensin II and orexins in 3T3 L1 preadipocyte cells proliferation and oxidative metabolism. J Physiol Pharmacol 2007;58(suppl 1):53-64.
11. Knoll J: Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand 1983;95:57-80.
12. Holschneider DP, Chen K, Seif I, Shih JC: Biochemical, behavioral, physiologic, and neurodevelopmental changes in mice deficient in monoamine oxidase A or B. Brain Res Bull 2001;56:453-462.
13. Knoll J: The striatal dopamine dependency of life span in male rats: longevity study with (-)deprenyl. Mech Ageing Dev 1988;46:237-262.
14. Birkmayer W, Knoll J, Riederer P, Youdim MB, Hars V, Marton J: Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm 1985;64:113-127.
15. Stoll S, Hafner U, Kranzlin B, Muller WE: Chronic treatment of Syrian hamsters with low-dose selegiline increases life span in females but not males. Neurobiol Aging 1997;18:205-211.
16. Bickford PC, Adams CE, Boyson SJ, Curella P, Gerhardt GA, Heron C, Ivy GO, Lin AM, Murphy MP, Poth K, Wallace DR, Young DA, Zahniser NR, Rose GM: Long-term treatment of male F344 rats with deprenyl: assessment of effects on longevity, behavior, and brain function. Neurobiol Aging 1997;18:309-318.
17. Tolbert SR, Fuller MA: Selegiline in treatment of behavioral and cognitive symptoms of Alzheimer disease. Ann Pharmacother 1996;30:1122-1129.
18. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ: A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216-1222.
19. Ruehl WW, Entriken TL, Muggenburg BA, Bruyette DS, Griffith WC, Hahn FF: Treatment with L-deprenyl prolongs life in elderly dogs. Life Sci 1997;61:1037-1044.
20. Kitani K, Minami C, Isobe K, Maehara K, Kanai S, Ivy GO, Carrillo MC: Why (-)deprenyl prolongs survivals of experimental animals: increase of anti-oxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects. Mech Ageing Dev 2002;123:1087-1100.
21. Muller T, Kuhn W, Kruger R, Przuntek H: Selegiline as immunostimulant:a novel mechanism of action? J Neural Transm Suppl 1998;52:321-328.
22. ThyagaRajan S, Madden KS, Kalvass JC, Dimitrova SS, Felten SY, Felten DL: L-deprenyl-induced increase in IL-2 and NK cell activity accompanies restoration of noradrenergic nerve fibers in the spleens of old F344 rats. J Neuroimmunol 1998;92:9-21.
23. De la Cruz CP, Revilla E, Rodriguez-Gomez JA, Vizuete ML, Cano J, Machado A: Deprenyl treatment restores serum insulin-like growth factor-I (IGF-I) levels in aged rats to young rat level. Eur J Pharmacol 1997;327:215-220.
24. ThyagaRajan S, Felten DL: Modulation of neuroendocrine-immune signaling by L-deprenyl and L-desmethyldeprenyl in aging and mammary cancer. Mech Ageing Dev 2002;123:1065-1079.
25. Mocchegiani E, Muzzioli M, Cipriano C, Giacconi R: Zinc, T-cell pathways, aging: role of metallothioneins. Mech Ageing Dev 1998;106:183-204.
26. Ferro JM, Madureira S: Age-related white matter changes and cognitive impairment. J Neurol Sci 2002;203-204:221-225.
27. Smith RG, Leonard R, Bailey AR, Palyha O, Feighner S, Tan C, McKee KK, Pong SS, Griffin P, Howard A: Growth hormone secretagogue receptor family members and ligands. Endocrine 2001;14:9-14.
28. Broglio F, Gottero C, Benso A, Prodam F, Destefanis S, Gauna C, Maccario M, Deghenghi R, van der Lely AJ, Ghigo E: Effects of ghrelin on the insulin and glycemic responses to glucose, arginine, or free fatty acids load in humans. J Clin Endocrinol Metab 2003;88:4268-4272.
29. Kojima M, Hosoda H, Kangawa K: Purification and distribution of ghrelin: the natural endogenous ligand for the growth hormone secretagogue receptor. Horm Res 2001;56:93-97.
30. Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, Bhattacharya S, Carpenter R, Grossman AB, Korbonits M: The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002;87:2988.
31. Hattori N, Saito T, Yagyu T, Jiang BH, Kitagawa K, Inagaki C: GH, GH receptor, GH secretagogue receptor, and ghrelin expression in human T cells, B cells, and neutrophils. J Clin Endocrinol Metab 2001;86:4284-4291.
32. Donini LM, Savina C, Cannella C: Eating habits and appetite control in the elderly: the anorexia of aging. Int Psychogeriatr 2003;15:73-87.
33. Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, Matsukura S, Kangawa K, Nakazato M: Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000;141:4255-4261.
34. Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T, Suda M, Koh T, Natsui K, Toyooka S, Shirakami G, Usui T, Shimatsu A, Doi K, Hosoda H, Kojima M, Kangawa K, Nakao K: Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 2001;86:4753-4758.
35. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-432.
36. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S: Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995;1:1155-1161.
37. Faggioni R, Feingold KR, Grunfeld C: Leptin regulation of the immune response and the immunodeficiency of malnutrition. FASEB J 2001;15:2565-2571.
38. Lee GH, Proenca R, Montez JM, Carroll KM, Darvishzadeh JG, Lee JI, Friedman JM: Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996;379:632-635.
39. Rosicka M, Krsek M, Jarkovska Z, Marek J, Schreiber V: Ghrelin, a new endogenous growth hormone secretagogue. Physiol Res 2002;51:435-441.
40. Brambilla F, Ferrari E, Panerai A, Manfredi B, Petraglia F, Catalano M, Sacerdote P: Psychoimmunoendocrine investigation in anorexia nervosa. Neuropsychobiology 1993;27:9-16.
41. Constans T: Malnutrition in the elderly. Rev Prat 2003;53:275-279.
42. Rossner S: Obesity in the elderly, a future matter of concern? Obes Rev 2001;2:183-188.
43. Loktionov A: Common gene polymorphisms and nutrition: emerging links with pathogenesis of multifactorial chronic diseases. J Nutr Biochem 2003;14:426-451.
44. Groopman JE: Fatigue in cancer and HIV/ AIDS. Oncology 1998;12:335-344.
45. Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, Hayashi T, Inoue G, Hosoda K, Kojima M, Kangawa K, Nakao K: Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 2001;50:227-232.
46. Kalra SP, Kalra PS: Neuropeptide Y: A Physiological orexigen modulated by the feedback action of ghrelin and leptin. Endocrine 2003;22:49-56.
47. Schmidt RE: Neuropathology and pathogenesis of diabetic autonomic neuropathy. Int Rev Neurobiol 2002;50:257-292.
48. Fabris N, Mocchegiani E, Provinciali M: Plasticity of neuroendocrine-thymus interactions during aging. Exp Gerontol 1997;32:415-429.
49. Hipkiss AR: Carnosine, a protective, antiageing peptide? Int J Biochem Cell Biol 1998;30:863-868.
50. De Marchis S, Melcangi RC, Modena C, Cavaretta I, Peretto P, Agresti C, Fasolo A: Identification of the glial cell types containing carnosine-related peptides in the rat brain. Neurosci Lett 1997;237:37-40.
51. McFarland GA, Holliday R: Retardation of the senescence of cultured human diploid fibroblasts by carnosine. Exp Cell Res 1994;212:167-175.
52. Wang AM, Ma C, Xie ZH, Shen F: Use of carnosine as a natural anti-senescence drug for human beings. Biochemistry (Mosc) 2000;65:869-871.
53. Trombley PQ, Horning MS, Blakemore LJ: Interactions between carnosine and zinc and copper: implications for neuromodulation and neuroprotection. Biochemistry (Mosc) 2000;65:807-816.
54. Preston JE, Hipkiss AR, Himsworth DT, Romero IA, Abbott JN: Toxic effects of β-amyloid(25-35) on immortalised rat brain endothelial cell: protection by carnosine, homocarnosine and beta-alanine. Neurosci Lett 1998;242:105-108.
55. Hyland P, Duggan O, Hipkiss A, Barnett C, Barnett Y: The effects of carnosine on oxidative DNA damage levels and in vitro lifespan in human peripheral blood derived CD4+ T cell clones. Mech Ageing Dev 2000;121:203-215.
56. Naito Y, Yoshikawa T, Yagi N, Matsuyama K, Yoshida N, Seto K, Yoneta T: Effects of polaprezinc on lipid peroxidation, neutrophil accumulation, and TNF-α expression in rats with aspirin-induced gastric mucosal injury. Dig Dis Sci 2001;46:845-851.
57. Mocchegiani E, Giacconi R, Cipriano C, Muzzioli M, Gasparini N, Moresi R, Stecconi R, Suzuki H, Cavalieri E, Mariani E: Mtm-RNA gene expression, via IL-6 and glucocorticoids, as potential genetic marker of immunosenescence: lessons from very old mice and humans. Exp Gerontol 2002;37:349-357.
58. Zakhidov ST, Gopko AV, Semenova ML, Mikhaleva YY, Makarov AA, Kulibin AY: Carnosine modifies the incidence of genetically abnormal sex cells in the testes of senescence-accelerated mice. Bull Exp Biol Med 2002;134:78-80.
59. Maret W, Vallee BL: Thiolate ligands in metallothionein confer redox activity on zinc clusters. Proc Natl Acad Sci USA 1998;95:3478-3482.
60. 2+ and NO to form products with a g = 2.039 ESR signal. Biochem Biophys Res Commun 1993;196:632-635.
61. St Croix CM, Wasserloos KJ, Dineley KE, Reynolds IJ, Levitan ES, Pitt BR: Nitric oxide-induced changes in intracellular zinc homeostasis are mediated by metallothionein/ thionein. Am J Physiol Lung Cell Mol Physiol 2002;282:L185-L192.
62. Kroncke KD, Carlberg C: Inactivation of zinc finger transcription factors provides a mechanism for a gene regulatory role of nitric oxide. FASEB J 2000;14:166-173.
63. Gergel D, Cederbaum AI: Inhibition of the catalytic activity of alcohol dehydrogenase by nitric oxide is associated with S nitrosylation and the release of zinc. Biochemistry 1996;35:16186-16194.
64. Zangger K, Oz G, Haslinger E, Kunert O, Armitage IM: Nitric oxide selectively releases metals from the amino-terminal domain of metallothioneins: potential role at inflammatory sites. FASEB J 2001;15:1303-1305.
65. Mocchegiani E, Muzzioli M, Giacconi R: Zinc and immunoresistance to infection in aging: new biological tools. Trends Pharmacol Sci 2000;21:205-208.
66. Delledonne M, Polverari A, Murgia I: The functions of nitric oxide-mediated signaling and changes in gene expression during the hypersensitive response. Antioxid Redox Signal 2003;5:33-41.
67. Malavolta M, Cipriano C, Costarelli L, Giacconi R, Tesei S, Muti E, Piacenza F, Pierpaoli S, Larbi A, Pawelec G, Dedoussis G, Herbein G, Monti D, Jajte J, Rink L, Mocchegiani E: Metallothionein downregulation in very old age: a phenomenon associated with cellular senescence? Rejuvenation Res 2008;11:455-459.
68. Mocchegiani E, Giacconi R, Cipriano C, Muzzioli M, Fattoretti P, Bertoni-Freddari C, Isani G, Zambenedetti P, Zatta P: Zinc-bound metallothioneins as potential biological markers of ageing. Brain Res Bull 2001;55:147-153.
69. 2+: a novel ionic mediator of neural injury in brain disease. Trends Pharmacol Sci 2000;21:395-401.
70. Mocchegiani E, Bertoni-Freddari C, Marcellini F, Malavolta M: Brain, aging and neurodegeneration: role of zinc ion availability. Prog Neurobiol 2005;75:367-390.
71. Masoro EJ: Caloric restriction and aging: an update. Exp Gerontol 2000;35:299-305.
72. Mocchegiani E, Giacconi R, Costarelli L, Muti E, Cipriano C, Tesei S, Pierpaoli S, Giuli C, Papa R, Marcellini F, Gasparini N, Pierandrei R, Piacenza F, Mariani E, Monti D, Dedoussis G, Kanoni S, Herbein G, Fulop T, Rink L, Jajte J, Malavolta M: Zinc deficiency and IL-6 -174G/C polymorphism in old people from different European countries: Effect of zinc supplementation. ZINC-AGE study. Exp Gerontol 2008;43:433-444.